| Identification | Back Directory | [Name]
[1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- | [CAS]
2011801-48-0 | [Synonyms]
PPARγ agonist 3
[1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- | [Molecular Formula]
C24H23N3O | [MOL File]
2011801-48-0.mol | [Molecular Weight]
369.46 |
| Hazard Information | Back Directory | [Uses]
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib[1]. | [References]
[1] Schoepf AM, et al. Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators. Eur J Med Chem. 2020 Jan 1;185:111748. DOI:10.1016/j.ejmech.2019.111748 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|